Sell-side analysts still seem to be nervous about the near-term future of the spine market, but investors haven't let that scare them away from NuVasive (NUVA). With new products and a focused OUS strategy re-accelerating growth and management laying out some bold ambitions for the next five years, these shares have more than doubled over the past year. This move doesn't have the shares looking particularly cheap these days, but if expectations for ortho M&A stay in place and NuVasive continues to take share from large rivals like Johnson & Johnson (JNJ) and Medtronic (MDT), I don't think the Street will get all that concerned about valuation.
Turbulence In The Spine...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: